SAUDI ARABIA – EVA Pharma and the Saudi Authority for Industrial Cities and Technology Zones (Modon) have joined forces to construct a full-fledged pharmaceutical industrial complex in Sudair in the Kingdom of Saudi Arabia.

Under the terms of this contract, EVA Pharma will acquire a 50,517 square meter plot of land, facilitated by Modon, in the city of Sudair to establish its cutting-edge research and manufacturing facility.

The Sudair industrial complex is expected to cater to a diverse spectrum of therapeutic domains in the pharmaceutical segment.

In an official statement, Riad Armanious, Chief Executive Officer of EVA Pharma, said: “EVA Pharma is not just scaling its physical presence in the Kingdom of Saudi Arabia; we are planting deep roots here. Our commitment to the Saudi people’s health is steadfast, and our investment in local manufacturing serves as a testament to this commitment.”

With the groundbreaking ceremony scheduled for late 2023, the first manufacturing phase is set to begin in April 2025.

The industrial complex will house a state-of-the-art Research & Development (R&D) center and five pharmaceutical factories.

These pharmaceutical factories include a biologics and oncology products facility, an oral dosage forms facility, an immunosuppressants facility, and a vaccine production unit.

Leveraging specialized containment technology, the industrial complex will produce over 150 pharmaceutical products spanning biologics, vaccines, immunosuppressants, oncology, and high-potency medications.

The industrial complex is expected to reach full operational capacity in 2026, with a production capacity of 990 million units annually.

Thanks to the unwavering support of the Saudi Food and Drug Authority (SFDA), we can expand on our mission and contribute to the well-being of the Saudi community as a local emerging manufacturer in the Kingdom,” said Armanious.

A new industrial sector in Saudi Arabia

The establishment of EVA Pharma’s new complex is poised to generate approximately 807 employment prospects, while concurrently playing a pivotal role in fostering the expansion of the local economy.

In addition, EVA Pharma’s investment in domestic manufacturing serves as a distinct manifestation of the company’s overarching dedication to bolstering the pharmaceutical capabilities of the region.

It is a clear reflection of the company’s commitment to fostering innovation, catalyzing technology transfer, and generating employment prospects.

We aim to be more than just a pharmaceutical company; we aspire to be a trusted partner in healthcare and to contribute to Saudi’s national health goals in line with the Saudi Vision 2030,” underlined Armanious.

EVA Pharma is one of the fastest-growing pharmaceutical companies in the Middle East and Africa (MEA) region.

The pharmaceutical company manufactures more than one million packs of over 300 healthcare solutions on a daily basis at its three internationally accredited facilities.

Eva Pharma’s selection of Sudair for its full-fledged pharmaceutical industrial complex demonstrates its confidence in the investment climate in the Kingdom of Saudi Arabia.

It serves as a testament to the pharmaceutical company’s ongoing efforts to significantly contribute to the growth and prosperity of the region.

In collaboration with Modon, EVA Pharma has selected IO, a German consultancy specializing in the implementation of complex industrial projects, to design and build its industrial complex.

EVA Pharma’s new site will incorporate a green circular economy approach as a component of the company’s endeavors to reduce waste and enhance resource utilization via innovative technologies.

The soon-to-be-launched industrial complex is projected to become a center of gravity for pharmaceutical manufacturing in the MEA region.

Harnessing the advanced medical capabilities of EVA Pharma, the complex is well-placed to meet the ever-evolving patient needs through research and collaboration with local universities and hospitals.

We recognize the need to work collaboratively with healthcare professionals and institutions to develop tailored solutions to the most demanding health challenges in the Kingdom of Saudi Arabia,” observed the Chief Executive Officer of EVA Pharma.

The strategic partnership initiated by Modon with Eva Pharma comes within the framework of its role to localize the medical and pharmaceutical industries in the Kingdom of Saudi Arabia.

Comparably, Modon has signed a SAR500 million (US$133.30 million) investment agreement with the Vaccine Industrial Company to set up a joint venture factory in Sadeer City.

Modon aims to create an ideal environment attractive to foreign investments and strengthen the national export system as an important factor for achieving a prosperous economy.

Consequently, the partnership between Modon with Eva Pharma aligns seamlessly with the objectives of the National Industrial Strategy and the aspirations of the Saudi Vision 2030.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.